Can the HPV vaccine protect transplant patients? new study investigates

NCT ID NCT05557370

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well the HPV9 vaccine (Gardasil 9) works in people who have had a kidney transplant. Researchers will measure antibody levels in 30 transplant recipients over 24 months and compare them to published data from healthy individuals. The goal is to see if the vaccine provides similar protection against HPV in this vulnerable group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Froedtert Lutheran Memorial Hospital

    Milwaukee, Wisconsin, 53226, United States